Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: Results from a Chinese center

Wu, Huifeng; Peng, Kangqiang; Ji, Zhijuan; Sun, Jianhua; Zhang, Q.; Yang, Xi; Huang, Chaoqun; Li, Y.

doi:10.1016/j.ejso.2016.04.053

Cited by 27 publications

(25 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is adequate evidence to judge the safety profile of CRS þ HIPEC for treating GC PM (Table 4) [13,[15][16][17][18][19][20]25,[27][28][29]31,[35][36][37][38][39]. In terms of adverse events, the most frequent adverse events include pleural effusion, ileus, sepsis, wound infection, occlusion, hypoalbuminemia and anastomosis leakage.…”

Section: Crs 1 Hipec Trials For Gc Pmmentioning

confidence: 99%

Current status and future prospects of clinical trials on CRS + HIPEC for gastric cancer peritoneal metastases

Peng

et al. 2017

International Journal of Hyperthermia

View full text Add to dashboard Cite

show abstract

Section: Crs 1 Hipec Trials For Gc Pmmentioning

confidence: 99%

Current status and future prospects of clinical trials on CRS + HIPEC for gastric cancer peritoneal metastases

Peng

et al. 2017

International Journal of Hyperthermia

View full text Add to dashboard Cite

show abstract

“…(30)(31)(32)(33)(34)(35)(36), prophylactic IPC/HIPEC for gastric cancer patients with serosa invasion (Table 2) (37-53), and therapeutic IPC/HIPEC for gastric cancer patients with macroscopic PC(Table 3)(42,47,(54)(55)(56)(57)(58)(59)(60)(61)(62)(63)(64)(65)(66)(67).…”

mentioning

confidence: 99%

Intraperitoneal free cancer cells in gastric cancer: pathology of peritoneal carcinomatosis and rationale for intraperitoneal chemotherapy/hyperthermic intraperitoneal chemotherapy in gastric cancer

Peng

2016

Transl. Gastroenterol. Hepatol.

View full text Add to dashboard Cite

Peritoneal carcinomatosis (PC) is one of the most common causes of death in gastric cancer patients. Intraperitoneal free cancer cells (IFCCs) play a very important role in forming PC, but the administration of intraperitoneal chemotherapy (IPC) and/or hyperthermic intraperitoneal chemotherapy (HIPEC) could be an effective treatment for IFCCs. This review focuses on the origin of IFCCs, the mechanism of PC formatting, the rationale of IPC/HIPEC, and the current clinical trials on IPC/HIPEC to treat advanced gastric cancer patients.

show abstract

“…In our initial search aimed at QoL after CRS and HIPEC in GC, the relevant information was found in 8 papers. Only one of these was devoted solely to GC, but because of the lack of objective QoL data, it was rejected as being an insufficient source of information [14].…”

Section: Resultsmentioning

confidence: 99%

Data on the quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies: does it concern patients with gastric cancer?

Skierucha

Połom

Rawicz‐Pruszyński

et al. 2017

Current Issues in Pharmacy and Medical Sciences

View full text Add to dashboard Cite

Introduction. So far there are no reports devoted exclusively to the quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in metastatic gastric cancer. Current literature concerning this issue was, thus, reviewed in order to: 1) search for such data concerning metastatic gastric cancer; 2) assess if the latest reviews evenly pertain to all peritoneal surface malignancies; and 3) conclude if they are a reliable source of data for patients with metastatic gastric cancer. Materials and Methods. The electronic PubMed/MEDLINE and EMBASE databases were retrieved for studies concerning the influence of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on quality of life in patients with metastatic gastric cancer and regardless of initial diagnosis. The data on the number of patients with particular tumours were analysed and the results were presented in the form of a table. Results. Approximately half of all patients encompassed by the reviews had a form of primary peritoneal surface malignancies. Within peritoneal metastases, the most numerous were colorectal (21-24%) and ovarian cancers (5-15%). Gastric cancers and sarcomas were the smallest defined subgroups (4% each). Conclusions. The promising outcomes in quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in primary peritoneal surface malignancies might differ from rarely reported ones in metastatic gastric cancer. The problem needs further, gastric cancer-devoted investigations.

show abstract

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: Results from a Chinese center

Abstract: CRS+HIPEC with lobaplatin and docetaxel to treat selected GC PC could improve OS, with acceptable perioperative safety.

Cited by 27 publications

References 35 publications

Current status and future prospects of clinical trials on CRS + HIPEC for gastric cancer peritoneal metastases

Current status and future prospects of clinical trials on CRS + HIPEC for gastric cancer peritoneal metastases

Intraperitoneal free cancer cells in gastric cancer: pathology of peritoneal carcinomatosis and rationale for intraperitoneal chemotherapy/hyperthermic intraperitoneal chemotherapy in gastric cancer

Data on the quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies: does it concern patients with gastric cancer?

Contact Info

Product

Resources

About